Nasdaq

Myriad Genetics Study Shows Increased Completion Rates for Hereditary Cancer Testing Through Online Screening and Education Tools

Myriad Genetics, Inc. announced a study indicating that the use of its online screening tool, MyGeneHistory®, alongside a virtual education program, significantly increased the completion rates for ...

Genetics in Medicine Open Study Demonstrates How Ambry Genetics’ ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing

Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced peer-reviewed research demonstrating the potential for variant-specific ...
Nasdaq

Myriad Genetics Study Finds GeneSight Test Reduces Psychiatric Hospitalizations in Major Depressive Disorder Patients

Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations in ...
Cure Today

23andMe, Advocacy Organizations Partner on Lung Cancer Genetics Study

23andMe and 20 lung cancer advocacy organizations are working to improve lung cancer detection, risk reduction and care. 23andMe, the genetic health and biopharmaceutical company, has partnered with ...
Business Wire

New Study Shows Impact of Ambry Genetics’ Patient for Life™ Program on Rare Disease Diagnosis

Peer-reviewed publication examines the benefits of proactive exome reanalysis on diagnostic outcomes Ambry Genetics’ Patient for Life program is supported by a dedicated team of scientists who ...
EurekAlert!

Study: Major gaps block genetics evaluation and testing for Black and low income patients

PHILADELPHIA— Black patients and patients from socioeconomically disadvantaged neighborhoods are dramatically under-represented in genetics clinics—often at rates half or less than those of White ...